{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-011987","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.755807+00:00","generated_at":"2026-05-15T23:39:36.771604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rhythm Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results; IMCIVREE Revenue $57.3M in Q4","bullets":["Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.","FDA PDUFA date March 20, 2026 for setmelanotide in acquired hypothalamic obesity.","Positive end-of-Phase-2 meeting with FDA for bivamelagon in acquired HO; Phase 3 trial to start by end of 2026.","Cash and investments $388.9M at Dec 31, 2025; net loss $48.8M in Q4 2025 vs $44.6M in Q4 2024.","Topline data expected March 2026 from Phase 3 EMANATE trial and Japanese cohort in acquired HO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-011987","json":"https://secwatch.observer/filing/0001628280-26-011987.json","markdown":"https://secwatch.observer/filing/0001628280-26-011987.md","text":"https://secwatch.observer/filing/0001628280-26-011987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/0001628280-26-011987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T23:39:36.771604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}